SkinBioTherapeutics PLC AxisBiotix-Ps(TM) to launch on Amazon UK (1351V)

TIDMSBTX

RNS Number : 1351V

SkinBioTherapeutics PLC

30 November 2023

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

AxisBiotix-Ps(TM) to launch on Amazon UK

30 November 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health announces that its AxisBiotix-Ps(TM) food supplement will launch on Amazon.co.uk from Wednesday, 6 December 2023 at 9am.

The launch of a sales channel through Amazon is a key part of the commercialisation strategy to expand market share for AxisBiotix-Ps(TM). The first Amazon launch is in the UK; the aim is then to extend product availability through other Amazon country sites. Management is already proactively seeking to expand online sales of its AxisBiotix-Ps(TM) into the European countries where the product has regulatory clearance (France, Italy and Spain).

AxisBiotix-Ps(TM) first went on sale to UK in October 2021 and is intended for customers to alleviate sensitive skin conditions such as psoriasis. The response from customers continues to be very positive with the retention rates of AxisBiotix-Ps(TM) in the UK staying at 80% or above. If access to the product can be made simpler, via an online channel like Amazon which is familiar to the majority of people, then management believes this will boost sales and marketing efforts.

According to Mintel, approximately 90% of the UK adult population uses Amazon. In 2019 alone, the UK e-commerce market was the largest in Europe and third largest to China and the US. Amazon held 30% of this market, and has shown ambitions in the beauty and skincare markets, with the launch of its own-brand skin care line, Belei. It has also teamed up with beauty major, L'Oreal.

Stuart J. Ashman, CEO of SkinBioTherapeutics, said : "The skin care market is a significant market, w ith an increasing global focus on health and well-being, and the demand for science-backed supplements is at an all-time high. The primary focus for AxisBiotix-Ps(TM) is growing our share of the market and using a sales channel like Amazon, which we use everyday, makes good strategic sense. We hope to announce the European launches on Amazon before the end of the year."

-Ends-

 
For more information please contact: 
  SkinBioTherapeutics plc                      Tel: +44 (0) 191 
   Stuart J. Ashman, CEO                        495 7325 
   Manprit Randhawa, CFO 
  Cavendish Capital Markets Limited            Tel: [phone] 
   (Nominated Adviser & Broker)                 0500 
   Giles Balleny, Dan Hodkinson (Corporate 
   Finance) 
   Charlie Combe (Broking) 
   Dale Bellis, Tamar Cranford-Smith (Sales) 
  Instinctif Partners (financial press)        Tel: [phone] 
   Melanie Toyne-Sewell / Jack Kincade          2020 
                                                [e-mail] 
 
 
 
 
 Notes to Editors 
 About SkinBioTherapeutics plc 
 SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary 
 platform technology, SkinBiotix(R), is based upon discoveries made by Professor Catherine 
 O'Neill and Professor Andrew McBain. 
 The Company is targeting a number of skin healthcare sectors, the most advanced of which are 
 cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin 
 axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. 
 The Company's first product, AxisBiotix-Ps(TM), a food supplement to address the symptoms 
 of mild to moderate psoriasis. 
 The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, 
 visit : www.skinbiotherapeutics.com and www.axisbiotix.com. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PRLDGBDBUXDDGXC

(END) Dow Jones Newswires

November 30, 2023 02:00 ET (07:00 GMT)